Effect of RSPO3 on inhibiting the growth of colorectal cancer transplanted tumors and increasing NK cell infiltration in vivo

doi:10.19401/j.cnki.1007-3639.2023.07.004

Abstract

Abstract:

Background and purpose: The occurrence and development of colorectal cancer involve the activation of multiple oncogenes and the inactivation of tumor suppressor genes. At present, the role of wild-type R-spondin 3 (RSPO3) in the growth of colorectal cancer is still unclear. This study aimed to investigate the effect of RSPO3 on the growth of colorectal cancer and explore the underlying mechanisms. Methods: RSPO3 expression in various tumor tissues and adjacent tissues and the relationships between RSPO3 expression and natural killer (NK) cell infiltration and activating molecules in colorectal cancer tissues were analyzed by bioinformatics. RSPO3-knockdown SW480 (SW480-RSPO3-KD) and RSPO3-overexpressed HCT116 (HCT116-RSPO3-OE) gene modification cell line as well as their control cell lines were established by short hairpin RNA (shRNA) and lentiviral infection. Cell proliferation in vitro were detected using cell counting kit-8 (CCK-8). Cell cycle of colon cancer stable cells and the proportion of NK cells in spleen and transplanted tumor tissues of nude mice were determined by flow cytometry. The growth of SW480-RSPO3-KD and HCT116-RSPO3-OE stable cell subcutaneous xenografts in vivo was observed in BALB/c nude mice. The Wnt gene activity was detected by dual-luciferase reporter system. Results: Expression level of RSPO3 was low in a variety of solid tumor tissues including colorectal cancer tissues compared to their adjacent normal tissues. RSPO3 knockdown or overexpression did not affect cell proliferation (P>0.05) and cell cycle in colon cancer cells in vitro (P>0.05). Surprisingly, RSPO3 knockdown significantly promoted the growth of SW480 subcutaneous xenograft tumor (260.2±162.4 vs 1 311.7±570.1, P<0.05). RSPO3 overexpression significantly inhibited the growth of HCT116 subcutaneous xenograft tumor (1 549.0±241.2 vs 512.1±250.0, P<0.05). Flow cytometry analysis showed that the percentages of NK cells in spleen and xenograft tissues were significantly decreased in mice transplanted with RSPO3-KD cells compared with control nude mice transplanted with control cells (spleen:6.42±0.94 vs 5.25±0.59, P=0.04; transplanted tumor: 8.27±0.29 vs 6.48±1.48, P=0.04). The percentage of NK cells was significantly increased in mice transplanted with RSPO3-OE cells compared with control mice transplanted with control cells (spleen: 5.29±0.16 vs 7.02±0.49, P=0.01; transplanted tumor: 6.39±0.39 vs 8.14 ±0.34, P<0.05). The Cancer Genome Atlas (TCGA) data analysis showed that expression of RSPO3 was positively correlated with the expressions of NK cell markers CD56 (R=0.58, P<0.05) and CD16 (R=0.64, P<0.05), and with the expressions of NK cell activation markers CD69 (R=0.51, P<0.05) and KLRB1 (R=0.37, P<0.05). RSPO3 knockdown inhibited the activity of Wnt luciferase (1.00±0.00 vs 0.45±0.09, P<0.05), and RSPO3 overexpression increased the Wnt luciferase activity in colon cancer cells (1.00±0.00 vs 1.75±0.14, P<0.05). Conclusion: RSPO3 can significantly inhibit the growth of colorectal cancer xenograft in vivo and increase NK cell frequency and Wnt activity in colon cancer cells. RSPO3 may be a potential colorectal cancer suppressor.

Key words: R-spondin 3, Natural killer cell, Colorectal cancer, Tumor growth

CLC Number:

ZHOU Cong, HE Lina, CHENG Xiaojiao, HUANG Tinglei, TU Shuiping. Effect of RSPO3 on inhibiting the growth of colorectal cancer transplanted tumors and increasing NK cell infiltration in vivo[J]. China Oncology, 2023, 33(7): 664-672.

Figures/Tables 6

Fig. 1

Fig. 2

Fig. 3

Fig. 4

Fig. 5

Fig. 6

References 28

[1]	AOKI M, MIEDA M, IKEDA T, et al. R-spondin3 is required for mouse placental development[J]. Dev Biol, 2007, 301(1): 218-226. doi: 10.1016/j.ydbio.2006.08.018 pmid: 16963017
[2]	KNIGHT M N, HANKENSON K D. R-spondins: novel matricellular regulators of the skeleton[J]. Matrix Biol, 2014, 37: 157-161. doi: 10.1016/j.matbio.2014.06.003 pmid: 24980904
[3]	NILSSON K H, HENNING P, EL SHAHAWY M, et al. RSPO3 is important for trabecular bone and fracture risk in mice and humans[J]. Nat Commun, 2021, 12(1): 4923. doi: 10.1038/s41467-021-25124-2 pmid: 34389713
[4]	KAZANSKAYA O, OHKAWARA B, HEROULT M, et al. The Wnt signaling regulator R-spondin 3 promotes angioblast and vascular development[J]. Development, 2008, 135(22): 3655-3664. doi: 10.1242/dev.027284 pmid: 18842812
[5]	KURTOVA A V, HEINLEIN M, HAAS S, et al. Disruption of stem cell niche-confined R-spondin 3 expression leads to impaired hematopoiesis[J]. Blood Adv, 2023, 7(4): 491-507. doi: 10.1182/bloodadvances.2022007714
[6]	LOH N Y, MINCHIN J E N, PINNICK K E, et al. RSPO3 impacts body fat distribution and regulates adipose cell biology in vitro[J]. Nat Commun, 2020, 11(1): 2797. doi: 10.1038/s41467-020-16592-z pmid: 32493999
[7]	KUROKAWA K, WANG T C, HAYAKAWA Y. R-spondin 3 governs secretory differentiation in the gastric oxyntic glands[J]. J Clin Invest, 2022, 132(21): e163380. doi: 10.1172/JCI163380
[8]	OGASAWARA R, HASHIMOTO D, KIMURA S, et al. Intestinal lymphatic endothelial cells produce R-spondin 3[J]. Sci Rep, 2018, 8(1): 10719. doi: 10.1038/s41598-018-29100-7
[9]	GREICIUS G, KABIRI Z, SIGMUNDSSON K, et al. PDGFRα⁺ pericryptal stromal cells are the critical source of Wnts and RSPO3 for murine intestinal stem cells in vivo[J]. Proc Natl Acad Sci U S A, 2018, 115(14): E3173-E3181.
[10]	YAN K S, JANDA C Y, CHANG J L, et al. Non-equivalence of Wnt and R-spondin ligands during Lgr5⁺ intestinal stem-cell self-renewal[J]. Nature, 2017, 545(7653): 238-242. doi: 10.1038/nature22313
[11]	ANNUNZIATO S, SUN T, TCHORZ J S. The RSPO-LGR4/5-ZNRF3/RNF43 module in liver homeostasis, regeneration, and disease[J]. Hepatology, 2022, 76(3): 888-899. doi: 10.1002/hep.32328
[12]	KUANG S Q, TONG W G, YANG H, et al. Genome-wide identification of aberrantly methylated promoter associated CpG islands in acute lymphocytic leukemia[J]. Leukemia, 2008, 22(8): 1529-1538. doi: 10.1038/leu.2008.130 pmid: 18528427
[13]	KANEDA H, ARAO T, TANAKA K, et al. FOXQ1 is overexpressed in colorectal cancer and enhances tumorigenicity and tumor growth[J]. Cancer Res, 2010, 70(5): 2053-2063. doi: 10.1158/0008-5472.CAN-09-2161 pmid: 20145154
[14]	THEODOROU V, KIMM M A, BOER M, et al. MMTV insertional mutagenesis identifies genes, gene families and pathways involved in mammary cancer[J]. Nat Genet, 2007, 39(6): 759-769. doi: 10.1038/ng2034 pmid: 17468756
[15]	TER STEEGE E J, BOER M, TIMMER N C, et al. R-spondin 3 is an oncogenic driver of poorly differentiated invasive breast cancer[J]. J Pathol, 2022, 258(3): 289-299. doi: 10.1002/path.v258.3
[16]	GU H F, TU H, LIU L L, et al. RSPO3 is a marker candidate for predicting tumor aggressiveness in ovarian cancer[J]. Ann Transl Med, 2020, 8(21): 1351. doi: 10.21037/atm-20-3731 pmid: 33313096
[17]	CHEN Z H, ZHOU L J, CHEN L, et al. RSPO3 promotes the aggressiveness of bladder cancer via Wnt/β-catenin and Hedgehog signaling pathways[J]. Carcinogenesis, 2019, 40(2): 360-369. doi: 10.1093/carcin/bgy140 pmid: 30329043
[18]	CHEN Z L, ZHANG J Z, YUAN A W, et al. R-spondin 3 promotes the tumor growth of choriocarcinoma JEG-3 cells[J]. Am J Physiol Cell Physiol, 2020, 318(3): C664-C674. doi: 10.1152/ajpcell.00295.2019
[19]	TANG Y T, XU Q, HU L, et al. Tumor microenvironment-derived R-spondins enhance antitumor immunity to suppress tumor growth and sensitize for immune checkpoint blockade therapy[J]. Cancer Discov, 2021, 11(12): 3142-3157. doi: 10.1158/2159-8290.CD-20-0833
[20]	SESHAGIRI S, STAWISKI E W, DURINCK S, et al. Recurrent R-spondin fusions in colon cancer[J]. Nature, 2012, 488(7413): 660-664. doi: 10.1038/nature11282
[21]	TANG Y, ZHOU C, LI Q L, et al. Targeting depletion of myeloid-derived suppressor cells potentiates PD-L1 blockade efficacy in gastric and colon cancers[J]. Oncoimmunology, 2022, 11(1): 2131084. doi: 10.1080/2162402X.2022.2131084
[22]	焦红丽, 王珺娆, 胡敏萱, 等. SAFB通过调节Wnt信号通路活性促进结直肠癌增殖[J]. 临床与实验病理学杂志, 2022, 38(4): 385-391
	JIAO H L, WANG J R, HU M X, et al. SAFB promotes colorectal cancer proliferation by regulating Wnt signaling pathway activity[J]. Chin J Clin Exp Pathol, 2022, 38(4): 385-391
[23]	RHODES D R, KALYANA-SUNDARAM S, MAHAVISNO V, et al. Oncomine 3.0: genes, pathways, and networks in a collection of 18 000 cancer gene expression profiles[J]. Neoplasia, 2007, 9(2): 166-180. doi: 10.1593/neo.07112
[24]	GHANDI M, HUANG F W, JANÉ-VALBUENA J, et al. Next-generation characterization of the cancer cell line encyclopedia[J]. Nature, 2019, 569(7757): 503-508. doi: 10.1038/s41586-019-1186-3
[25]	RU B B, WONG C N, TONG Y, et al. TISIDB: an integrated repository portal for tumor-immune system interactions[J]. Bioinformatics, 2019, 35(20): 4200-4202. doi: 10.1093/bioinformatics/btz210 pmid: 30903160
[26]	TANG Z F, LI C W, KANG B X, et al. GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses[J]. Nucleic Acids Res, 2017, 45(W1): W98-W102. doi: 10.1093/nar/gkx247
[27]	RUSSICK J, TORSET C, HEMERY E, et al. NK cells in the tumor microenvironment: prognostic and theranostic impact. Recent advances and trends[J]. Semin Immunol, 2020, 48: 101407. doi: 10.1016/j.smim.2020.101407
[28]	OHKAWARA B, GLINKA A, NIEHRS C. RSPO3 binds syndecan 4 and induces Wnt/PCP signaling via clathrin-mediated endocytosis to promote morphogenesis[J]. Dev Cell, 2011, 20(3): 303-314. doi: 10.1016/j.devcel.2011.01.006 pmid: 21397842